Search Results 521-530 of 17403 for alopecia

  1. Memory loss: When to seek help - Mayo Clinic

    5X Challenge is here! 5X My Gift! Your gift today can have 5X the impact on AI research and technology. But hurry — the match challenge ends 9/19. 5X My Gift!

  2. Mayo Clinic

    The peripheral nervous system is all the nerves in your body, aside from the ones in your brain and spinal cord. It acts as a communication relay between ...

  3. Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma - Mayo Clinic

    residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose ...

  4. Yes, Babies and Children Get Cataracts, Too - Mayo Clinic

    Hello. My name is Eric Bothun. I'm a pediatric eye surgeon at the Mayo Clinic in Rochester, Minnesota, caring for kids of all ages and eye diseases.

  5. A Study to Evaluate Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma - Mayo Clinic

    ... alopecia. Patients who have endocrinopathies associated with prior immunotherapy treatment but which are controlled with replacement therapy are eligible ...

  6. A Study to Compare Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients - Mayo Clinic

    Patients with vitiligo or alopecia Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement Any chronic skin ...

  7. A Study to Evaluate IMGN632 with Venetoclax and/or Azacitidine to Treat Patients with CD123-Positive Acute Myeloid Leukemia - Mayo Clinic

    Previous treatment-related toxicities must have resolved to Grade 1 or baseline (excluding alopecia). Total white blood cell count must be less than 25 × 10 ...

  8. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors - Mayo Clinic

    Note: Except patients with ≤ Grade 2 neuropathy or any grade of alopecia. Has tumor(s) invading a major vascular structure (e.g., carotid artery) or other ...

  9. A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma - Mayo Clinic

    Resolution of all acute adverse events resulting from prior cancer therapies to NCI CTCAE grade ≤ 1 or baseline (except alopecia or neuropathy); Adequate ...

  10. Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). - Mayo Clinic

    Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not ...